A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age with Achondroplasia: PROPEL 3
Primary Objective
To evaluate the efficacy of infigratinib in pediatric subjects with ACH 3 to <18 years of age.
Details
Age
Child
Eligibility
Age 3 to <18 years of age with growth potential defined as AHV of >1.5cm/year over a period of at least 6 months.Confirmed diagnosis of ACH via genetic testing, 6 months participation in PROPEL study prior to study entry, and able to swallow study medication.
Locations
Childrens Hospital Colorado
Principal Investigator
Klane White
Study ID
Protocol Number: 23-2112
More information available at ClinicalTrials.gov: NCT04035811
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers